Gone are the days in which healthcare communications solely come from the physician office’s landline. | 58% of patients out ...
Leo Pharma appears to be second guessing its plans for a 2026 initial public offering. | Ownership behind Danish ...
Japanese Big Pharma Eisai is teaming up with Boston-based digital health company Linus Health to create new “Brain Health ...
Continuing to harvest a bounty of autumn approvals, AstraZeneca has picked up nods for its C5 inhibitor gefurulimab to treat ...
The FDA has issued a complete response letter to Summit Therapeutics, derailing the immediate U.S. launch of a drug class ...
The FDA has quietly shelved the Commissioner’s National Priority Voucher (CNPV) pilot program, a controversial speedy review ...
Genentech has unlocked a new chapter in its patient-forward “Life Doesn’t Wait” campaign for hemophilia A drug Hemlibra with ...
Earlier this year, AZ fired another shot in bladder cancer when Imfinzi was cleared by the FDA alongside Bacillus ...
Merck KGaA just secured an FDA approval for its new once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, ...
Summit Therapeutics is gearing up for ivonescimab’s high-stakes FDA decision without its chief commercial officer (CCO) ...
With Lantheus in the process of being bought out by fellow radiopharmaceutical player Curium, the company is offloading its ...
With a positive classification from the DEA paving the way for Orzeyful’s U.S. launch on Thursday, Takeda is charting new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results